stockrowOmeros Corporation (OMER) vs Urogen Pharma (URGN)
- Omeros Corporation OMER 16.83 −1.41%
- Urogen Pharma URGN 24.81 −3.58%
Omeros Corporation and Urogen Pharma are both Biotechnology companies. Omeros Corporation and Urogen Pharma are of similar size ($1.3B and $1.2B). Urogen Pharma has negative trailing earnings, so its P/E is not meaningful; Omeros Corporation trades at 9.8×. Urogen Pharma grew revenue faster over the last twelve months: 159.3% against 36.3%. Omeros Corporation has the higher net margin (128.4% vs −26.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Urogen Pharma leads on 9 and Omeros Corporation on 7.
Valuation
Profitability
| Metric | OMER | URGN | Biotechnology median |
|---|---|---|---|
| Gross margin | 37.57% | 91.41% | 68.51% |
| Operating margin | (74.88%) | (12.36%) | 0.00% |
| Net margin | 128.36% | (26.27%) | 0.00% |
| Free cash flow margin | (70.69%) | (52.77%) | 0.00% |
| Return on equity | (89.15%) | 54.65% | (51.96%) |
| Return on assets | 51.22% | (28.78%) | (46.06%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack